Glasdegib
![]() | |
Clinical data | |
---|---|
Synonyms | PF-04449913 |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
KEGG | |
Chemical and physical data | |
Formula | C21H22N6O |
Molar mass | 374.45 g·mol−1 |
3D model (JSmol) | |
| |
|
Glasdegib (PF-04449913) is an experimental cancer drug developed by Pfizer. It is a small molecule inhibitor of the Sonic hedgehog pathway, which is overexpressed in many types of cancer. It inhibits smoothened receptor, as do most drug in its class.[1]
Four phase II clinical trials are in progress. One is evaluating the efficacy of glasdegib in treating myelofibrosis in patients who were unable to control the disease with ruxolitinib.[2] Another is a combination trial of glasdenib with ARA-C, decitabine, daunorubicin, or cytarabine for the treatment of acute myeloid leukemia.[3] The third is for the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.[4] The fourth administers glasdegib to patients at high risk for relapse after stem cell transplants in acute lymphoblastic or myelogenous leukemia.[5]
References
- ↑ "Glasdegib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
- ↑ "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
- ↑ "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
- ↑ "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
- ↑ "PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.